Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Baxter International Inc    BAX

Delayed Quote. Delayed  - 09/26 10:01:38 pm
47.2 USD   -0.61%
09/26 BAXTER INTERNAT : Ranked as One of the Most Diverse and Inclusive Wo..
09/22 BAXTER INTERNAT : Foundation and Direct Relief Launch a Mobile Healt..
09/21 Intermountain Healthcare Announces 2016 Supplier Award Winners
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Baxter International Inc. : Baxter's Investigational Hemophilia Treatment Yields Positive Results

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/10/2012 | 03:34pm CEST
    By Saabira Chaudhuri 
 

Baxter International Inc. (BAX) said results from a study evaluating its investigational treatment for patients with hemophilia B were positive.

The medical product company's BAX 326--its investigational recombinant factor IX protein for the treatment and prophylaxis of bleeding episodes for patients with hemophilia B over 12 years of age--was recently granted orphan-drug designation by the U.S. Food and Drug Administration.

"With only one recombinant protein currently available to treat hemophilia B, it was important to focus research efforts on finding another option for patients with this debilitating disease," Lead Investigator Jerzy Windyga said. "In this study, more than 40 percent of patients using BAX 326 as a prophylactic treatment experienced no bleeds, an important finding given the potentially harmful impact of bleeding episodes for patients."

The study investigated the efficacy and safety of BAX 326 in 73 previously treated patients with severe or moderately severe hemophilia B.

Baxter noted that hemophilia B is the second most common type of hemophilia--also known as Christmas disease--and is the result of insufficient amounts of clotting factor IX, a naturally occurring protein in blood that controls bleeding. The company added that about 25,000 people world-wide, including more than 4,000 in the U.S., have been diagnosed with hemophilia B.

Baxter's profits have improved for more than a year on strong demand for its hemophilia and immunodeficiency products. Its bottom line has been less pressured by the slowdown in health-care spending, compared with some peers, because Baxter focuses on medical devices and pharmaceuticals used to treat life-threatening ailments and injuries.

In October, Baxter said its third-quarter earnings rose 1.2% as the company's margins improved, though sales were short of its prior guidance.

Shares closed Friday at $65.07 and were inactive in recent premarket trading. The stock has risen 32% so far this year.

Write to Saabira Chaudhuri at saabira.chaudhuri@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAXTER INTERNATIONAL INC
09/26 BAXTER INTERNATIONAL : Ranked as One of the Most Diverse and Inclusive Workplace..
09/22 BAXTER INTERNATIONAL : Foundation and Direct Relief Launch a Mobile Health Initi..
09/21 Intermountain Healthcare Announces 2016 Supplier Award Winners
09/19 BAXTER LAUNCHES NUMETA G13E IN EUROP : Only Ready-to-Use IV Nutrition for Vulner..
09/19 SUNSHINE HEART : Announces Strategic Acquisition of Aquadex Product Line from Ba..
09/14 BAXTER INTERNATIONAL : Foundation Supports Program Training the Next Generation ..
09/01 BAXTER INTERNATIONAL : and Satellite Healthcare Partner to Bring Innovative Dial..
08/31 BAXTER INTERNATIONAL INC : ex-dividend day
08/25 BAXTER INTERNATIONAL : and Satellite Healthcare Partner to Bring Innovative Dial..
08/16 BAXTER INTERNATIONAL : to Present at the Morgan Stanely Global Healthcare Confer..
More news
Sector news : Medical Equipment, Supplies & Distribution - NEC
09/17DJJ&J to Buy Abbott Eye Business -- WSJ
09/16DJJ&J to Buy Abbott's Eye-Surgery Unit for $4.325 billion -- 2nd Update
09/16DJJ&J to Buy Abbott's Eye-Surgery Unit for $4.325 billion -- 3rd Update
09/16DJJ&J to Buy Abbott's Eye-Surgery Unit for $4.325 billion -- Update
09/16DJJ&J Nears Deal to buy Abbott's Eye-Surgery Equipment Unit
More sector news : Medical Equipment, Supplies & Distribution - NEC
News from SeekingAlpha
09/20 Shire cools to pacritinib, intends to return to CTI Biopharma
09/19 Baxter launches NUMETA G13E in Europe for preterm newborns at risk for malnut..
09/16 Healthcare ratings roundup - new coverage
08/31 Are We Approaching A Key Inflection Point In The Biotech Sector?
08/23 5 Buys From The Narrow-Moat Universe
Advertisement
Financials ($)
Sales 2016 10 157 M
EBIT 2016 1 225 M
Net income 2016 2 098 M
Debt 2016 198 M
Yield 2016 1,05%
P/E ratio 2016 11,47
P/E ratio 2017 26,74
EV / Sales 2016 2,56x
EV / Sales 2017 2,48x
Capitalization 25 829 M
More Financials
Chart BAXTER INTERNATIONAL INC
Duration : Period :
Baxter International Inc Technical Analysis Chart | BAX | US0718131099 | 4-Traders
Full-screen chart
Technical analysis trends BAXTER INTERNATIO...
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 15
Average target price 50,5 $
Spread / Average Target 6,2%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
José E. Almeida Chairman, President & Chief Executive Officer
James K. Saccaro Chief Financial Officer & Vice President
Paul E. Martin Chief Information Officer & Vice President
Marcus Schabacker Chief Scientific Officer
John D. Forsyth Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BAXTER INTERNATIONAL I..24.48%25 829
MEDTRONIC PLC14.03%121 210
ZIMMER BIOMET HOLDINGS..25.09%25 668
C R BARD INC21.36%16 888
SYSMEX CORP-4.87%15 655
TERUMO CORP6.47%15 064
More Results